Martin Shkreli, the hedge fund manager who triggered an outcry by putting a 5,000 percent markup on its lifesaving drug, has gone to war with business news channel CNBC, reports Dylan Byers of CNNMoney.
Byers writes, “According to CNBC host Scott Wapner, Shkreli wanted to come on CNBC to defend another drug company, Valeant Pharmaceuticals, against accusations of accounting fraud. CNBC told Shkreli they would also have to talk to him about the elephant in the room — his decision to jack up the price of the toxoplasmosis drug Daraprim from $18 a pill to $750 a pill. He said no.
“Shkreli tells a slightly different version: CNBC had asked him to come on and talk about Valeant, then said they wanted to talk about Turing Pharmaceuticals as well. ‘I tell them to pound sand,’ Shkreli wrote on Twitter.
“Shkreli instead went to Fox Business Network on Friday morning, where he defended his price gouging in an interview with Maria Bartiromo.”
Read more here.
